Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
6827175 | Schizophrenia Research | 2012 | 7 Pages |
Abstract
This study found no benefit of adjunctive armodafinil versus placebo for negative symptoms in patients with schizophrenia receiving treatment with olanzapine, risperidone, or paliperidone. Armodafinil was generally well tolerated in these patients.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
John M. Kane, Ronghua Yang, James M. Youakim,